Skip to main content

Table 4 FIS values and differences from baseline.

From: Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study

Time points and periods

Parameters

Total Group

Treatment-naive group

Pre-treated group

Baseline (B)

Mean (SD)

60.53 (34.24)

56.25 (32.65)

65.51 (35.54)

 

Median

59.00

55.00

70.00

 

95% CI (mean)

55.72; 65.34

49.97; 62.54

58.10; 72.91

Month 6 (M6)

Mean (SD)

51.15 (35.35)

45.68 (33.33)

57.79 (36.76)

 

Median

44.50

40.00

50.00

 

95% CI (mean)

45.83; 56.47

38.81; 52.54

49.36; 65.83

Month 12 (M12)

Mean (SD)

54.07 (35.18)

47.97 (33.78)

61.46 (35.62)

 

Median

49.00

43.50

63.00

 

95% CI (mean)

48.88; 59.26

41.20; 54.74

53.58; 69.33

Change B to M6

Mean (SD)

-9.17 (27.08)***

-11.33 (27.67)***

-6.62 (26.32)*

 

Median

-6.00

-7.00

-3.00

 

95% CI (mean)

-13.24; -5.09

-17.03; -5.64

-12.51; -0.73

Change B to M12

Mean (SD)

-6.04 (29.04)**

-8.50 (29.35)**

-3.06 (28.57)

 

Median

-5.00

-8.00

-3.00

 

95% CI (mean)

-10.32; -1.76

-14.38; -2.62

-9.38; 3.25

  1. SD, standard deviation; CI, confidence interval; ***, p < 0.001; **, p < 0.01; *, p < 0.05. Differences between groups were not statistically tested.